Answers are grounded in this paper and cite their sources.
Medulloblastoma (MB) is the most common malignant pediatric brain tumor and remains a major cause of cancer-related morbidity and mortality in children. Although multimodal therapies have significantly improved survival for many patients, children with high-risk, metastatic, or recurrent MB continue to face limited therapeutic options and severe treatment-related complications. Immunotherapy has emerged as a promising strategy. However, clinical responses to conventional immune-based approaches, particularly immune checkpoint blockade, have been modest due to the low immunogenicity, immunosuppressive tumor immune microenvironment (TIME), and substantial molecular heterogeneity of MB. Recent advances in single-cell sequencing, spatial profiling, and molecular classification have revealed that MB consists of distinct biological entities with unique immune landscapes and therapeutic vulnerabilities. These findings have shifted the field from nonspecific immune activation toward precision-guided immunotherapeutic strategies. Several cellular therapies have subsequently been investigated, including chimeric antigen receptor (CAR)-T cells, T-cell receptor (TCR)-engineered T cells, and gamma delta (γδ) T-cell therapies. These approaches have shown encouraging activity in preclinical models; early clinical studies of CAR-T cells support the feasibility of locoregional delivery in pediatric central nervous system (CNS) tumors, although objective responses remain limited and MB-specific efficacy is unestablished. γδ T-cell and TCR-engineered approaches remain preclinical in MB. However, challenges including antigen heterogeneity, immune escape, limited immune-cell trafficking across the central nervous system barriers, and tumor microenvironment-mediated resistance remain major obstacles. This paper summarizes the current understanding of the MB immune microenvironment. It also discusses recent advances in immunotherapeutic strategies, particularly precision cellular therapies. Future strategies involve multi-omics profiling, cellular engineering, and adjustments to the tumor microenvironment. Individualized immunotherapy guided by tumor molecular identity and the immune ecosystem may offer a new approach to improving outcomes in children with high-risk MB.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: